BioMarin Pharmaceutical Inc. (BMRN)
BMRN Price and Sentiment
BMRN Latest news
BMRN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving BioMarin Pharmaceutical Inc.
2021-11-11 20:49New York, New York--(Newsfile Corp. - November 11, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=21107&wire=5
BMRN Shareholder Alert: Rosen, Recognized Investor Counsel, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BMRN
2021-11-11 19:15New York, New York--(Newsfile Corp. - November 11, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the "Class Period"), of the important December 22, 2021 lead plaintiff deadline.SO WHAT: If you purchased BioMarin securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2021-11-11 15:07Los Angeles, California--(Newsfile Corp. - November 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between January 13, 2020, and September 3, 2021, inclusive...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2021 - BMRN
2021-11-11 12:58New York, New York--(Newsfile Corp. - November 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get more information...
BioMarin Pharmaceutical Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against BioMarin Pharmac
2021-11-11 11:33NEW YORK, Nov. 11, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) in the United States District Court for the Northern District of California, on behalf of a class consisting of all persons and entities that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021, both dates inclusive (the "Class Period"). All investors who purchased BioMarin Pharmaceutical Inc. a nd incurred losses are u rged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.
BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 22, 2021 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders
2021-11-10 22:38New York, New York--(Newsfile Corp. - November 10, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) alleging that the Company violated federal securities laws.Class Period: January 13, 2020 and September 3, 2021Lead Plaintiff Deadline: December 22, 2021No obligation or cost to you.Learn more about your recoverable losses in BMRN:https://www.kleinstocklaw.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?id=21056&from=5
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
2021-11-10 21:00NEW YORK--(BUSINESS WIRE)-- #BioMarin--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired BioMarin securities between January 1, 2020 and September 3, 2021, both dates inclusive (the “Cla
BioMarin Shareholder Alert
2021-11-10 18:15Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In BioMarin To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - November 10, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) and reminds investors of the December 22, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.If you suffered losses exceeding $50,000 investing in BioMarin stock or options between...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2021 - (BMRN)
2021-11-10 16:40New York, New York--(Newsfile Corp. - November 10, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).Shareholders who purchased shares of BMRN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biomarin-pharmaceutical-inc-loss-submission-form-2/?id=21036&from=5
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2021-11-10 15:05Los Angeles, California--(Newsfile Corp. - November 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between January 13, 2020, and September 3, 2021, inclusive...